Arecor Therapeutics plc Stock

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Delayed London S.E. 04:24:39 2024-04-19 am EDT 5-day change 1st Jan Change
127 GBX -1.17% Intraday chart for Arecor Therapeutics plc -7.64% -30.41%
Sales 2023 * 5.01M 6.24M Sales 2024 * 7.58M 9.44M Capitalization 39.36M 48.98M
Net income 2023 * -6M -7.47M Net income 2024 * -6M -7.47M EV / Sales 2023 * 6.62 x
Net cash position 2023 * 6.17M 7.68M Net cash position 2024 * 2.08M 2.59M EV / Sales 2024 * 4.92 x
P/E ratio 2023 *
-5.35 x
P/E ratio 2024 *
-5.98 x
Employees 51
Yield 2023 *
-
Yield 2024 *
-
Free-Float 48.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.17%
1 week-7.64%
Current month-9.29%
1 month-13.90%
3 months-24.63%
6 months-33.16%
Current year-30.41%
More quotes
1 week
125.00
Extreme 125
138.00
1 month
125.00
Extreme 125
150.00
Current year
125.00
Extreme 125
184.00
1 year
125.00
Extreme 125
299.00
3 years
125.00
Extreme 125
472.00
5 years
125.00
Extreme 125
472.00
10 years
125.00
Extreme 125
472.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 -
Director of Finance/CFO 65 18-12-31
Chief Tech/Sci/R&D Officer - 07-07-31
Members of the board TitleAgeSince
Director/Board Member 78 -
Director/Board Member 66 21-04-30
Chairman 64 -
More insiders
Date Price Change Volume
24-04-19 127 -1.17% 2 502
24-04-18 128.5 0.00% 0
24-04-17 128.5 -1.15% 247,000
24-04-16 130 -1.89% 16,323
24-04-15 132.5 -3.64% 17,907

Delayed Quote London S.E., April 19, 2024 at 04:24 am EDT

More quotes
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.285 GBP
Average target price
4.71 GBP
Spread / Average Target
+266.54%
Consensus

Annual profits - Rate of surprise